Aromatase Inhibitors Plus Weight Loss Improves the Hormonal Profile of Obese Hypogonadal Men Without Causing Major Side Effects

Georgia Colleluori, Rui Chen, Christie G Turin, Francesca Vigevano, Clifford Qualls, Biju Johnson, Sanjay Mediwala, Dennis T Villareal, Reina Armamento-Villareal, Georgia Colleluori, Rui Chen, Christie G Turin, Francesca Vigevano, Clifford Qualls, Biju Johnson, Sanjay Mediwala, Dennis T Villareal, Reina Armamento-Villareal

Abstract

Objective: In obese men, the increased expression of the aromatase enzyme in adipose tissue leads to high conversion of androgens to estrogens contributing to hypogonadotropic hypogonadism (HHG). Our objective is to evaluate efficacy and safety of weight loss (WL) plus aromatase inhibitor (AI) therapy in severely obese men with HHG. We hypothesize that AI+WL will be more effective as compared to WL alone in improving the hormonal profile, thus muscle strength and symptoms of HHG (primary outcomes), with no significant adverse effects on lean mass, metabolic profile, and bone mineral density (secondary outcomes). Design: Randomized double-blind placebo-controlled pilot trial. Methods: Twenty-three obese men (BMI≥35 kg/m2), 35-65 years old, were randomized to weight loss (diet and exercise) plus either anastrozole (AI+WL, n = 12) at 1 mg daily or placebo (PBO+WL, n = 11) for 6 months. Inclusion criteria: total testosterone <300 ng/mL (average of 2 measurements), estradiol≥10.9 pg/ml, LH <9 IU/l. Symptoms of hypogonadism by questionnaires; muscle strength by Biodex dynamometer; body composition and bone mineral density by dual-energy X-ray absorptiometry; bone microarchitecture and finite element analysis by high resolution peripheral quantitative-computed tomography. Results: After 6 months of therapy, AI+WL group had higher testosterone (p = 0.003) and lower estradiol (p = 0.001) compared to PBO+WL. Changes in symptoms and muscle strength did not differ between groups. AI+WL resulted in higher fat mass loss than PBO+WL (p = 0.04) without differences in changes in lean mass. Total and LDL cholesterol reduced more in the PBO+WL group compared to AI+WL (p = 0.03 for both), who experienced a minimal increase with unlikely meaningful clinical impact. Tibial trabecular bone area decreased more in PBO+WL than AI+WL group for which it remained stable (p = 0.03). Conclusions:Although AI+WL is effective in reversing the hormonal profile of HHG in severely obese men without causing major side effects, it does not lead to greater improvements in muscle strength and symptoms of hypogonadism compared to WL alone. Clinical Trial Registration: www.ClinicalTrials.gov, identifier: NCT02959853.

Keywords: aromatase inhibitors; body composition; bone density; bone microarchitecture; hypogonadism; obesity; sex hormones; weight loss.

Copyright © 2020 Colleluori, Chen, Turin, Vigevano, Qualls, Johnson, Mediwala, Villareal and Armamento-Villareal.

Figures

Figure 1
Figure 1
Consort diagram.
Figure 2
Figure 2
Mean serum Total Testosterone (A), Estradiol (B), FSH (C), and LH (D) levels at baseline, 3 and 6 months. I bars indicates standard deviation; p < 0.05 for comparison with the PBO+WL group is indicated by a star; adjusted p values for baseline value.
Figure 3
Figure 3
Absolute change (adjusted for baseline value) of body composition parameters at 6 months. (A) Weight Change; (B) Total Fat Change; (C) Body Fat Change; (D) Total Lean Change; (E) Truncal Fat Change; (F) Appendicular Lean Change. I bars indicated standard deviations; p < 0.05 is indicated by a star.

References

    1. Corona G, Rastrelli G, Monami M, Melani C, Balzi D, Sforza A, et al. . Body mass index regulates hypogonadism-associated CV risk: results from a cohort of subjects with erectile dysfunction. J Sex Med. (2011) 8:2098–105. 10.1111/j.1743-6109.2011.02292.x
    1. Pellitero S, Olaizola I, Alastrue A, Martinez E, Granada ML, Balibrea JM, et al. . Hypogonadotropic hypogonadism in morbidly obese males is reversed after bariatric surgery. Obes Surg. (2012) 22:1835–42. 10.1007/s11695-012-0734-9
    1. Giagulli VA, Kaufman JM, Vermeulen A. Pathogenesis of the decreased androgen levels in obese men. J Clin Endocrinol Metab. (1994) 79:997–1000. 10.1210/jcem.79.4.7962311
    1. Aguirre LE, Colleluori G, Dorin R, Robbins D, Chen R, Jiang B, et al. . Hypogonadal men with higher body mass index have higher bone density and better bone quality but reduced muscle density. Calcif Tissue Int. (2017) 101:602–11. 10.1007/s00223-017-0316-x
    1. Cohen PG. The hypogonadal-obesity cycle: role of aromatase in modulating the testosterone-estradiol shunt–a major factor in the genesis of morbid obesity. Med Hypotheses. (1999) 52:49–51. 10.1054/mehy.1997.0624
    1. Hayes FJ, Seminara SB, DeCruz S, Boepple PA, Crowley WF, Jr. (2000). Aromatase inhibition in the human male reveals a hypothalamic site of estrogen feedback. J Clin Endocrinol Metab. 85:3027–35. 10.1210/jcem.85.9.6795
    1. Strain GW, Zumoff B, Kream J, Strain JJ, Deucher R, Rosenfeld RS, et al. . Mild hypogonadotropic hypogonadism in obese men. Metabolism. (1982) 31:871–5. 10.1016/0026-0495(82)90175-5
    1. Corona G, Rastrelli G, Monami M, Saad F, Luconi M, Lucchese M, et al. . Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol. (2013) 168:829–43. 10.1530/EJE-12-0955
    1. Niskanen L, Laaksonen DE, Punnonen K, Mustajoki P, Kaukua J, Rissanen A. Changes in sex hormone-binding globulin and testosterone during weight loss and weight maintenance in abdominally obese men with the metabolic syndrome. Diabetes Obes Metab. (2004) 6:208–15. 10.1111/j.1462-8902.2004.00335.x
    1. Bray GA. Evaluation of drugs for treating obesity. Obes Res. (1995) 4(3 Suppl.):425S−34S. 10.1002/j.1550-8528.1995.tb00209.x
    1. Armamento-Villareal R, Aguirre LE, Qualls C, Villareal DT. Effect of lifestyle intervention on the hormonal profile of frail, obese older men. J Nutr Health Aging. (2016) 20:334–40. 10.1007/s12603-016-0698-x
    1. Leder BZ, Rohrer JL, Rubin SD, Gallo J, Longcope C. Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels. J Clin Endocrinol Metab. (2004) 89:1174–80. 10.1210/jc.2003-031467
    1. Zumoff B, Miller LK, Strain GW. Reversal of the hypogonadotropic hypogonadism of obese men by administration of the aromatase inhibitor testolactone. Metabolism. (2003) 52:1126–8. 10.1016/S0026-0495(03)00186-0
    1. Loves S, de Jong J, van Sorge A, Telting D, Tack CJ, Hermus A, et al. . Somatic and psychological effects of low-dose aromatase inhibition in men with obesity-related hypogonadotropic hypotestosteronemia. Eur.J.Endocrinol. (2013) 169:705–14. 10.1530/EJE-13-0190
    1. Dougherty RH, Rohrer JL, Hayden D, Rubin SD, Leder BZ. Effect of aromatase inhibition on lipids and inflammatory markers of cardiovascular disease in elderly men with low testosterone levels. Clin Endocrinol. (2005) 62:228–35. 10.1111/j.1365-2265.2005.02205.x
    1. Burnett-Bowie SA, Roupenian KC, Dere ME, Lee H, Leder BZ. Effects of aromatase inhibition in hypogonadal older men: a randomized, double-blind, placebo-controlled trial. Clin Endocrinol. (2009) 70:116–23. 10.1016/S0084-3741(09)79269-8
    1. Leder BZ, Finkelstein JS. Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men. Osteoporos Int. (2005) 16:1487–94. 10.1007/s00198-005-1890-8
    1. Burnett-Bowie SA, McKay EA, Lee H, Leder BZ. Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. J Clin Endocrinol Metab. (2009) 94:4785–92. 10.1210/jc.2009-0739
    1. Colleluori G, Aguirre L, Dorin R, Robbins D, Blevins D, Barnouin Y, et al. . Hypogonadal men with type 2 diabetes mellitus have smaller bone size and lower bone turnover. Bone. (2017) 99:14–9. 10.1016/j.bone.2017.03.039
    1. Weiss EP, Jordan RC, Frese EM, Albert SG, Villareal DT. Effects of weight loss on lean mass, strength, bone, and aerobic capacity. Med Sci Sports Exerc. (2017) 49:206–17. 10.1249/MSS.0000000000001074
    1. Armamento-Villareal R, Aguirre L, Napoli N, Shah K, Hilton T, Sinacore DR, et al. . Changes in thigh muscle volume predict bone mineral density response to lifestyle therapy in frail, obese older adults. Osteoporos Int. (2014) 25:551–8. 10.1007/s00198-013-2450-2
    1. Mohamed O, Freundlich RE, Dakik HK, Grober ED, Najari B, Lipshultz LI, et al. . The quantitative ADAM questionnaire: a new tool in quantifying the severity of hypogonadism. Int J Impot Res. (2010) 22:20–4. 10.1038/ijir.2009.35
    1. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. (1999) 11:319–26. 10.1038/sj.ijir.3900472
    1. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. (1997) 49:822–30. 10.1016/S0090-4295(97)00238-0
    1. Kolotkin RL, Crosby RD. Psychometric evaluation of the impact of weight on quality of life-lite questionnaire (IWQOL-lite) in a community sample. Qual Life Res. (2002) 11:157–71. 10.1037/t54236-000
    1. Armamento-Villareal R, Sadler C, Napoli N, Shah K, Chode S, Sinacore DR, et al. . Weight loss in obese older adults increases serum sclerostin and impairs hip geometry but both are prevented by exercise training. J Bone Miner Res. (2012) 27:1215–21. 10.1002/jbmr.1560
    1. Aguirre LE, Colleluori G, Fowler KE, Jan IZ, Villareal K, Qualls C, et al. . High aromatase activity in hypogonadal men is associated with higher spine bone mineral density, increased truncal fat and reduced lean mass. Eur J Endocrinol. (2015) 173:167–74. 10.1530/EJE-14-1103
    1. Vilayphiou N, Boutroy S, Szulc P, Van RB, Munoz F, Delmas PD, et al. . Finite element analysis performed on radius and tibia HR-pQCT images and fragility fractures at all sites in men. J Bone Miner Res. (2011) 26:965–73. 10.1002/jbmr.297
    1. Chiba K, Okazaki N, Kurogi A, Isobe Y, Yonekura A, Tomita M, et al. . Precision of second-generation high-resolution peripheral quantitative computed tomography: intra- and intertester reproducibilities and factors involved in the reproducibility of cortical porosity. J Clin Densitom. (2018) 21:295–302. 10.1016/j.jocd.2017.01.006
    1. Tajar A, Forti G, O'Neill TW, Lee DM, Silman AJ, Finn JD, et al. . Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European male ageing study. J Clin Endocrinol Metab. (2010) 95:1810–8. 10.1210/jc.2009-1796
    1. Napoli N, Shah K, Waters DL, Sinacore DR, Qualls C, Villareal DT. Effect of weight loss, exercise, or both on cognition and quality of life in obese older adults. Am J Clin Nutr. (2014) 100:189–98. 10.3945/ajcn.113.082883
    1. Newman AB, Lee JS, Visser M, Goodpaster BH, Kritchevsky SB, Tylavsky FA, et al. . Weight change and the conservation of lean mass in old age: the health, aging and body composition study. Am J Clin Nutr. (2005) 82:872–8. quiz 915–876. 10.1093/ajcn/82.4.872
    1. Colleluori G, Aguirre L, Phadnis U, Fowler K, Armamento-Villareal R, Sun Z, et al. . Aerobic plus resistance exercise in obese older adults improves muscle protein synthesis and preserves myocellular quality despite weight loss. Cell Metab. (2019) 30:261–73.e266. 10.1016/j.cmet.2019.06.008
    1. Singh R, Artaza JN, Taylor WE, Gonzalez-Cadavid NF, Bhasin S. Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology. (2003) 144:5081–8. 10.1210/en.2003-0741
    1. Finkelstein JS, Yu EW, Burnett-Bowie SA. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. (2013) 369:2457 10.1056/NEJMc1313169
    1. Bhasin S, Storer TW, Berman N, Yarasheski KE, Clevenger B, Phillips J, et al. . Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab. (1997) 82:407–13. 10.1210/jc.82.2.407
    1. Maffei L, Murata Y, Rochira V, Tubert G, Aranda C, Vazquez M, et al. . Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment. J Clin Endocrinol Metab. (2004) 89:61–70. 10.1210/jc.2003-030313
    1. Barros RP, Gustafsson JA. Estrogen receptors and the metabolic network. Cell Metab. (2011) 14:289–99. 10.1016/j.cmet.2011.08.005
    1. Palmisano BT, Zhu L, Stafford JM. Role of estrogens in the regulation of liver lipid metabolism. Adv Exp Med Biol. (2017) 1043:227–56. 10.1007/978-3-319-70178-3_12
    1. Colleluori G, Chen R, Napoli N, Aguirre LE, Qualls C, Villareal DT, et al. . Fat mass follows a U-shaped distribution based on estradiol levels in postmenopausal women. Front Endocrinol. (2018) 9:315. 10.3389/fendo.2018.00315
    1. Colleluori G, Aguirre LE, Qualls C, Chen R, Napoli N, Villareal DT, et al. . Adipocytes ESR1 expression, body fat and response to testosterone therapy in hypogonadal men vary according to estradiol levels. Nutrients. (2018) 10:1226. 10.3390/nu10091226
    1. Schneider G, Kirschner MA, Berkowitz R, Ertel NH. Increased estrogen production in obese men. J Clin Endocrinol Metab. (1979) 48:633–8. 10.1210/jcem-48-4-633
    1. Montagnani A, Gonnelli S, Cadirni A, Caffarelli C, Del Santo K, Pieropan C, et al. . The effects on lipid serum levels of a 2-year adjuvant treatment with exemestane after tamoxifen in postmenopausal women with early breast cancer. Eur J Intern Med. (2008) 19:592–7. 10.1016/j.ejim.2007.05.016
    1. Colleluori G., Chen R., Turin C, Vigevano F, Qualls C, Mediwala S, et al. MON-094 aromatase inhibitors and weight loss in severely obese male veterans with hypogonadism: a randomized clinical trial. J Endocr Soc. (2019) 3(Suppl. 1):MON-094 10.1210/js.2019-MON-094

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe